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Insulin and IGF-1, but not 17β-estradiol, 
alter the subcellular localization of MIER1α 
in MCF7 breast carcinoma cells
Shengnan Li, Gary D. Paterno and Laura L. Gillespie*
Abstract 
Background: MIER1α is a transcriptional regulator that interacts with estrogen receptor α and inhibits estrogen-
stimulated growth of breast carcinoma cells. Interestingly, analysis of MIER1α subcellular localization in breast samples 
revealed a stepwise shift from the nucleus to the cytoplasm during progression to invasive carcinoma. Previously, 
we demonstrated that MIER1α is nuclear in MCF7 cells yet it does not contain a nuclear localization signal. Instead 
MIER1α is targeted to the nucleus through interaction and co-transport with HDAC 1 and 2.
Results: In this study, we demonstrate that treatment of MCF7 breast carcinoma cells with either insulin or insulin-
like growth factor affects the subcellular localization of MIER1α. Both factors reduce the percentage of cells with 
nuclear MIER1α from 81 and 89 to 41 and 56 %, respectively. Treatment with 17β-estradiol, on the other hand, had no 
effect and MIER1α remained nuclear.
Conclusions: Our data demonstrate that insulin and IGF-1 can contribute to loss of nuclear MIER1α in the MCF7 
breast carcinoma cell line.
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Background
MIER1α is a transcriptional repressor [1, 2] that has been 
implicated as a tumour suppressor in breast cancer [3]. 
It interacts with ERα and inhibits estrogen-stimulated 
anchorage-dependent growth of breast carcinoma cells 
[3]. Moreover, analysis of patient breast biopsies revealed 
a dramatic reduction in nuclear MIER1α during progres-
sion, from 75  % nuclear MIER1α in normal samples to 
51 % nuclear in ductal carcinoma in situ to 4 % nuclear 
in invasive ductal carcinoma [3]. Thus loss of nuclear 
MIER1α is associated with breast cancer progression.
MIER1 represses transcription through several distinct 
mechanisms: it can recruit histone deacetylase (HDAC) 1 
and 2 to the promoter of responsive genes [1]; it can bind 
Creb binding protein (CBP) and inhibit its histone acetyl-
transferase activity [4]; finally, it can interact directly with 
transcription factors such as Sp1 and displace them from 
their cognate site on target gene promoters [2]. All of 
these functions are dependent on localization of MIER1α 
in the nucleus, yet it does not contain a functional NLS 
[5]. Instead, translocation into the nucleus is depend-
ent on interaction and co-transport with HDAC1 and 2 
[6]. In this report, we show that localization of MIER1α 
in the nucleus of MCF7 cells is significantly reduced by 
treatment with insulin or IGF-1, but not by 17β-estradiol 
(E2). This suggests that insulin or IGF-1 could attenuate 
MIER1α’s transcriptional repressor/chromatin modifying 
functions in MCF7.
Methods
The MCF7 breast carcinoma cell line was obtained from 
the ATCC and cultured in DMEM (GIBCO) containing 
10 % serum [7.5 % calf serum (CS) + 2.5 % fetal bovine 
serum (FBS)] (GIBCO), in a humidified 37  °C incubator 
with 5  % CO2. Insulin was purchased from Life Tech-
nologies and used at a concentration of 10ug/ml. IGF-1 
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was purchased from PeproTech and used at a concen-
tration of 10  ng/ml. 17β-estradiol was purchased from 
Sigma-Aldrich and used at a concentration of 10−8  M. 
For experiments using 17β-estradiol, cells were cultured 
in phenol red-free DMEM (GIBCO) supplemented with 
10 % charcoal-stripped FBS (Hyclone). Cells were treated 
for 4 h with insulin, IGF-1 or 17β-estradiol prior to fixa-
tion. Construction of the human mier1α sequence (Gen-
Bank: AY124188) in the CS3  +  MT vector has been 
described previously [1]. Transient transfection, confocal 
microscopy, antibodies used and Z-stack analysis were 
performed as described in [6, 7]. Subcellular localiza-
tion was scored as ‘nuclear’ if the nucleus was intensely 
stained, with little or no cytoplasmic staining; ‘cytoplas-
mic’ if staining was primarily in the cytoplasm, with lit-
tle or no staining in the nucleus; ‘whole cell’ if both the 
nucleus and cytoplasm were stained [6]. Statistical analy-
sis was performed using a two-sided Fisher’s exact test.
Results and discussion
Insulin alters nuclear localization of MIER1α in MCF7 cells
We have shown previously that MIER1α is targeted to 
the nucleus in MCF7 cells despite the lack of an intrinsic 
NLS [6, 7]. In those studies, cells were cultured in DMEM 
containing 10  % CS/FBS. Several laboratories, includ-
ing the ATCC, add 10  ug/ml insulin to culture media 
for MCF7 cells, however when we added insulin, we 
noticed a change in the subcellular localization pattern 
of MIER1α. To investigate this effect more thoroughly, 
we analysed mier1α-transfected MCF7 cells by confocal 
microscopy. In the presence of insulin, only 41 % of cells 
had exclusively nuclear MIER1α (Fig.  1Ad–f, B), com-
pared to 81 % of cells in the absence of insulin (Fig. 1Aa–
c, B). The percentage cells with MIER1α in both the 
nucleus and cytoplasm (whole cell staining) increased in 
the presence of insulin, from 18 to 42 % (Fig. 1B). Like-
wise, the proportion of cells with exclusively cytoplasmic 
MIER1α increased over tenfold, from 1 to 17 % (Fig. 1B). 
These results demonstrate that in the presence of insulin, 
localization of MIER1α in MCF7 cells is shifted from the 
nucleus to the cytoplasm.
Our previous research demonstrated that MIER1α 
localizes to the nucleus through interaction and co-trans-
port with HDAC1/2. Therefore we investigated whether 
insulin also affected localization of HDAC1/2. Confocal 
analysis demonstrated that while insulin reduces nuclear 
accumulation of MIER1α (Fig. 2Ab, f, j), it does not affect 
localization of HDAC1 or 2 (Fig. 2Ac, g, k) and both were 
100 % nuclear (Fig. 2B).
Nuclear accumulation of MIER1α is affected by IGF‑1, 
but not by E2
IGF-1 is closely related to insulin and both can interact 
with the insulin and IGF receptors, albeit with differing 
affinities [8]. In addition, there is a wealth of evidence 
implicating IGF-1 in breast cancer development and 
progression (reviewed in [9] ) and it has been shown to 
increase invasiveness of MCF7 cells [10]. Since MCF7 
cells express receptors for both insulin and IGFs [11], we 
explored the possibility that IGF-1 also affects localiza-
tion of MIER1α. As expected, confocal analysis dem-
onstrated that IGF-1 had a similar effect on nuclear 
accumulation of MIER1α (Fig. 3Ab, f, j, B). IGF-1 reduced 
the percentage of cells with nuclear MIER1α from 89 
to 56  % and increased the percentage with ‘whole cell’ 
staining from 10 to 40 %. The percent with ‘cytoplasmic’ 
MIER1α was also increased from 0.3 to 4 %. Thus, both 
insulin and IGF-1 have similar effects on the subcellular 
localization of MIER1α in MCF7.
Insulin and IGFs are potent mitogens for MCF7 cells 
[12], leading to the question of whether changes in 
nuclear accumulation of MIER1α are related to the fact 
that the cells are proliferating. We therefore examined 
MIER1α localization in cells treated with E2, a classic 
mitogen for ER + breast carcinoma cells. Unlike insulin 
and IGF-1, E2 had no significant effect on nuclear accu-
mulation of MIER1α (Fig. 4). In the presence of E2, 77 % 
of cells displayed nuclear MIER1α (Fig.  4Af, j, B) com-
pared to 80  % of untreated cells (Fig.  4Ab, B). Likewise 
there was no significant difference in the percentage of 
cells with ‘whole cell’ or ‘cytoplasmic’ staining (Fig. 4B). 
These results demonstrate that the shift in MIER1α local-
ization directed by insulin and IGF-1 is not the non-spe-
cific result of cell proliferation.
More than likely activation of one of the insulin/
IGF signalling pathways is responsible for the altered 
MIER1α localization in MCF7. This type of effect has 
been observed for the FOXO family of transcription fac-
tors. For example, FOXO is driven out of the nucleus by 
insulin as well as other growth factors [13] and by Src sig-
nalling [14]. In C. elegans, activation of DAF-2, the nema-
tode ortholog of the IGF-1 receptor, prevents nuclear 
accumulation of the DAF-16 (FOXO) transcription factor 
[15].
The data presented here demonstrate that for MCF7 
the culture conditions, specifically the common prac-
tice of including insulin in the medium, can have impor-
tant consequences for studies of nuclear proteins like 
MIER1α.
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Fig. 1 Insulin treatment reduces nuclear localization of MIER1α. MCF7 cells were transfected with myc-tagged mier1α and treated 24 h later with 
either vehicle (panels a–c) or 10 ug/ml insulin (panels d–f). Cells were fixed 4 h after the addition of insulin and localization was analyzed by confo-
cal microscopy. Random fields were selected and the staining pattern of each cell within the field was scored as ‘nuclear’, ‘whole cell’ or ‘cytoplasmic’, 
using sequential Z-stage scanning. A Shown are Z-stacks compiled into individual images, illustrating stained nuclei (DAPI; panels a, d), MIER1α 
localization (9E10 anti-myc tag antibody and an AlexaFluor-488 secondary antibody; panels b, e) and merged channels (panels c, f); arrowheads 
show examples of nuclear staining and arrows show whole cell staining. B Histogram showing the results of 3 independent experiments; the 
MIER1α localization pattern of >1000 cells was scored. Plotted is the percentage of cells in each category ±SD; Asterisk indicates that the difference 
was statistically significant, p < 0.05 (Fisher’s exact test)
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Fig. 2 HDAC1 and 2 localization are not affected by insulin. Cells were transfected, treated with insulin and prepared for confocal microscopy as 
described in Fig. 1. A Compiled Z-stacks showing nuclei (DAPI; panels a, e, i), MIER1α (AlexaFluor-488, panels b, f, j), HDAC1 (AlexaFluor-647, panels 
c, g), HDAC2 (AlexaFluor-647, panel k) and merged 488 and 647 channels (panels d, h, l); arrowheads show examples of nuclei and arrows show 
whole cell staining. B Histogram showing the localization of HDAC1 and HDAC2 in untreated (Con) and in insulin treated MCF7 cells; plotted is the 
percentage of cells in each category ±SD from three independent experiments
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Fig. 3 IGF-1 reduces nuclear localization of MIER1α. MCF7 cells were transfected with myc-tagged mier1α and treated 24 h later with either vehicle 
(panels a–d) or 10 ng/ml IGF-1 (panels e–l). Cells were fixed 4 h after the addition of IGF-1 and localization was analyzed by confocal microscopy, 
as in Fig. 1. A Compiled Z-stacks showing nuclei (DAPI; panels a, e, i), MIER1α (AlexaFluor-488, panels b, f, j), HDAC1 (AlexaFluor-647, panels c, g), 
HDAC2 (AlexaFluor-647, panel k) and merged 488 and 647 channels (panels d, h, l). B Histogram showing the results of two independent experi-
ments; the MIER1α localization pattern of >1000 cells was scored. Plotted is the percentage of cells in each category ±SD; Asterisk indicates that the 
difference was statistically significant, p < 0.05 (Fisher’s exact test). Note that nuclear localization of HDAC1 and HDAC2 was unaffected by IGF-1
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Fig. 4 E2 has no effect on subcellular localization of MIER1α. MCF7 cells were transfected with myc-tagged mier1α and 24 h later, either vehicle 
(panels a–d) or 10−8M E2 (panels e–l) was added. Cells were fixed 4 h later and localization was analyzed by confocal microscopy, as in Fig. 1. 
A Compiled Z-stacks showing nuclei (DAPI; panels a, e, i), MIER1α (AlexaFluor-488, panels b, f, j), HDAC1 (AlexaFluor-647, panels c, g), HDAC2 
(AlexaFluor-647, panel k) and merged 488 and 647 channels (panels d, h, l). B Histogram showing the results of two independent experiments; the 
MIER1α localization pattern of >500 cells was scored. Plotted is the percentage of cells in each category ±SD; there was no statistically significant 
difference between the percentage of control and E2 treated cells in each of the three categories, p > 0.05 (Fisher’s exact test)
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